News

The study evaluated verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with mild-to-moderate Alzheimer’s disease (AD). Merck said

LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology. In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in

Asubio Pharma has approximately 150 employees and mainly focuses on psychiatric and neurological diseases, immune and inflammatory diseases and regenerative medicine, conducting research based on its position a

The company is also making preparations for a phase III registration program that is expected begin in the second half of this year. The double-blind, randomized, placebo-controlled and

The divestiture from Sanofi will fulfill the European Commission’s requirement related to the former’s deal with German drugmaker Boehringer Ingelheim. The deal includes Prontalgine, an analgesic for the treatment

 RB CEO Rakesh Kapoor said: “The acquisition of Mead Johnson is a significant step forward in RB’s journey as a leader in consumer health. With the Enfa family

The study was conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). In the trial, TRC105 combined with Avastin (bevacizumab) was compared to

Cinven has proposed to buy all the shares of Stada in a takeover offer, with each of them priced at €56. The offer from the other unnamed bidder has

Under an exclusive global licensing agreement, Seattle Genetics will develop, fund, manufacture and commercialize Immunomedics’ solid tumor therapy candidate, IMMU-132. Seattle will also take the responsibility to start